Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc.

Overview
Date Founded

2002

Headquarters

2801 GATEWAY DRIVE, SUITE 150, IRVING, TX, 75063

Type of Company

Public

Employees (Worldwide)

123

Industries

Pharmaceuticals
Biotechnology

Company Description

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.

Contact Data
Trying to get in touch with decision makers at Reata Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chairman of the Board, Chief Executive Officer & President

Chief Financial Officer & Executive Vice President

Vice President & Chief Commercial Officer

Vice President, Chief Accounting Officer

Vice President, Chief Legal Officer

Executive Vice President-Operations

Chief Medical Officer & Executive Vice President, Product Development

Chief Development Officer & Senior Vice President, Regulatory

Chief Technical Officer & Senior Vice President, CMC

Vice President, Market Access

Board of Directors

Founder at Montrose Capital, Inc.

Chief Financial Officer at Aerin Medical, Inc.

Chairman of the Board, Chief Executive Officer & President at Reata Pharmaceuticals, Inc.

Partner at CPMG

Managing Director at Vivo Capital LLC

Co-Managing Director at Micro Focus (US), Inc.

Paths to Reata Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Reata Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

CPMG generally seeks to earn the highest risk-adjusted rate of return through fundamental research and portfolio management. They seek to analyze and invest in securities, which may include derivative instruments, that are either over-valued, in which case they will sell short the securities, or undervalued, in which case they will purchase the securities. The firm selects investments and allocates positions in those investments based on an expected value analysis taking into account downside risk, upside potential and the probabilities of those outcomes.CPMG may purchase or sell short debt securities, derivative instruments and contracts and other investments. They may take positions in companies with various sized market capitalizations, depending upon their analysis of the particular investment opportunity. As a part of their strategy, the firm may also acquire substantial ownership positions in a company, whether private or publicly traded, and may establish short positions with respect to a substantial percentage of the outstanding shares of a company. They may also invest in illiquid investments, which may include the purchase of securities of companies through private placements or through publicly announced corporate transactions such as spin-offs, tender offers, mergers, special dividends, restructuring and liquidations. Our decision to invest is based on the expected value and attractiveness of the investment relative to other investment opportunities.While CPMG's primary focus is on publicly-traded securities, opportunities may arise that will provide attractive rates of return outside the public markets. They may also, from time to time, invest in non-publicly traded securities that they believe are appropriate investments in conjunction with the funds objectives. Some of the funds employ specialized, limited or specific investment strategies and/or were organized for specific purposes or objectives, including each of the institutional funds. In addition, the Condire Funds generally focus on investments in natural resource exploration and development companies.

Details Hidden

Cormorant Asset Management manages a hedge fund and a private equity fund that focus on investments in the healthcare sector. The firm employs a fundamental, research intensive approach that focuses on primary research to identify investment opportunities.The objective of the hedge fund is to generate superior risk-adjusted returns with low market correlation. Cormorant seeks to accomplish this objective primarily through a combination of long investment positions and short selling to achieve capital appreciation while attempting to preserve capital and mitigate risk through hedging activities. The firm invests substantially, but not solely, in publicly traded equity securities in the healthcare and life science industries.The private equity fund's investment objective is to generate significant long-term capital appreciation by creating or investing in market innovative companies in the biotechnology and life sciences marketplace. Cormorant expects to achieve this objective by primarily investing in \"crossover\" (or mezzanine) round or pre-IPO portfolio companies in the biotech, medical device, diagnostics, generics, pharmaceutical, specialty pharmaceutical and life science research tool sectors. Cormorant, may also invest in portfolio companies through PIPEs and in start-up portfolio companies, including start-ups organized, managed and funded with Cormorant's or their affiliates' proprietary capital.

Details Hidden

Emerald Mutual Fund Advisers Trust (EMFAT) invests their clients' assets primarily in U.S. domestic equity securities. The firm's investment strategies include small-cap growth, small-cap value, and mid- and large-cap stocks. EMFAT employs intense fundamental, bottom-up research designed to identify unrecognized, under-researched, undervalued, as well as overvalued companies.

Recent Transactions
Details Hidden

Reata Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Reata Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Reata Pharmaceuticals, Inc. issued Class A Voting Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onReata Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onReata Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onReata Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onReata Pharmaceuticals, Inc. issued USD Common Stock

Associate

Advised onReata Pharmaceuticals, Inc. issued USD Common Stock

Associate

Advised onReata Pharmaceuticals, Inc. issued Class A Voting Common Stock

Clients

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It operates through the Pharmaceuticals and Bio-Chemicals segments. The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. The Bio-Chemicals segment produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Key Stats and Financials As of 2018
Market Capitalization
$6.88B
Total Enterprise Value
$1.3B
Earnings Per Share
$-2.91
Revenue
$53.6M
Net Profit
$-80.6M
EBITDA
$-76.4M
EBITDAMargin
-142.65%
Total Debt
$79.2M
Total Equity
$15.2M
Enterprise Value Sales
24.17x
TEVNet Income
-16.08x
Debt TEV
0.06x
Three Year Compounded Annual Growth Rate Of Revenue
2.12%
Investors
Details Hidden

CPMG generally seeks to earn the highest risk-adjusted rate of return through fundamental research and portfolio management. They seek to analyze and invest in securities, which may include derivative instruments, that are either over-valued, in which case they will sell short the securities, or undervalued, in which case they will purchase the securities. The firm selects investments and allocates positions in those investments based on an expected value analysis taking into account downside risk, upside potential and the probabilities of those outcomes.CPMG may purchase or sell short debt securities, derivative instruments and contracts and other investments. They may take positions in companies with various sized market capitalizations, depending upon their analysis of the particular investment opportunity. As a part of their strategy, the firm may also acquire substantial ownership positions in a company, whether private or publicly traded, and may establish short positions with respect to a substantial percentage of the outstanding shares of a company. They may also invest in illiquid investments, which may include the purchase of securities of companies through private placements or through publicly announced corporate transactions such as spin-offs, tender offers, mergers, special dividends, restructuring and liquidations. Our decision to invest is based on the expected value and attractiveness of the investment relative to other investment opportunities.While CPMG's primary focus is on publicly-traded securities, opportunities may arise that will provide attractive rates of return outside the public markets. They may also, from time to time, invest in non-publicly traded securities that they believe are appropriate investments in conjunction with the funds objectives. Some of the funds employ specialized, limited or specific investment strategies and/or were organized for specific purposes or objectives, including each of the institutional funds. In addition, the Condire Funds generally focus on investments in natural resource exploration and development companies.

Details Hidden

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation's assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

Details Hidden

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Suppliers
University of Kansas Private Equity & Venture Capital | Lawrence, KS

The University of Kansas (KU) is a public research university and the largest university in the State of Kansas. KU campuses are located in Lawrence, Wichita, Overland Park, Salina, and Kansas City, Kansas, with the main campus located in Lawrence on Mount Oread, the highest location in Lawrence. The University was opened in 1866, under a charter granted by the Kansas Legislature in 1864.

University of Texas - MD Anderson Cancer Center Medical Support Services | Houston, TX

The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 68 National Cancer Institute-designated comprehensive cancer centers today. U.S. News & World Report’s "Best Hospitals" survey has ranked MD Anderson as one of the nation’s top two cancer centers every year since the survey began in 1990.

Interpublic Group of Companies, Inc. Computer Software | New York, New York

Interpublic Group of Cos., Inc. engages in the provision of advertising and marketing services. The company specializes in consumer advertising, digital marketing, communications planning and media buying, public relations, and specialized communications disciplines. It operates through the following segments: Integrated Agency Network (IAN), Constituency Management Group (CMG), and Corporate and Other. The IAN segment includes advertising and media services, as well as a comprehensive array of global communications and marketing services. The CMG segment offers events and public relations services as well as sports and entertainment marketing, corporate and brand identity, and strategic marketing consulting. The Corporate and Other segment refers to the Acxiom activities. The company was founded on September 18, 1930 and is headquartered in New York, NY.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

United Therapeutics Corp. Pharmaceuticals - Silver Spring, Maryland

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Reata Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Reata Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Reata Pharmaceuticals, Inc..